850 related articles for article (PubMed ID: 17189415)
41. Both H-2- and non-H-2-linked genes influence influenza nucleoprotein epitope recognition by CD4+ T cells.
Brett SJ; Tite JP
Immunology; 1996 Jan; 87(1):42-8. PubMed ID: 8666434
[TBL] [Abstract][Full Text] [Related]
42. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
[TBL] [Abstract][Full Text] [Related]
43. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells.
Gallimore A; Hombach J; Dumrese T; Rammensee HG; Zinkernagel RM; Hengartner H
Eur J Immunol; 1998 Oct; 28(10):3301-11. PubMed ID: 9808199
[TBL] [Abstract][Full Text] [Related]
44. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
45. Antiviral immune responses of mice lacking MHC class II or its associated invariant chain.
Battegay M; Bachmann MF; Burhkart C; Viville S; Benoist C; Mathis D; Hengartner H; Zinkernagel RM
Cell Immunol; 1996 Jan; 167(1):115-21. PubMed ID: 8548834
[TBL] [Abstract][Full Text] [Related]
46. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
[TBL] [Abstract][Full Text] [Related]
47. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
48. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
50. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
51. In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb.
Puglielli MT; Zajac AJ; van der Most RG; Dzuris JL; Sette A; Altman JD; Ahmed R
J Virol; 2001 Jun; 75(11):5099-107. PubMed ID: 11333891
[TBL] [Abstract][Full Text] [Related]
52. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
53. A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells.
Oukka M; Riché N; Kosmatopoulos K
J Immunol; 1994 May; 152(10):4843-51. PubMed ID: 8176207
[TBL] [Abstract][Full Text] [Related]
54. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
55. Unexpected T-cell recognition of an altered peptide ligand is driven by reversed thermodynamics.
Allerbring EB; Duru AD; Uchtenhagen H; Madhurantakam C; Tomek MB; Grimm S; Mazumdar PA; Friemann R; Uhlin M; Sandalova T; Nygren PÅ; Achour A
Eur J Immunol; 2012 Nov; 42(11):2990-3000. PubMed ID: 22837158
[TBL] [Abstract][Full Text] [Related]
56. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
57. MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice.
Moskophidis D; Lechner F; Hengartner H; Zinkernagel RM
J Immunol; 1994 May; 152(10):4976-83. PubMed ID: 8176216
[TBL] [Abstract][Full Text] [Related]
58. Differential immune recognition of LCMV nucleoprotein and glycoprotein in transgenic mice expressing LCMV cDNA genes.
Zeller JC; Nguyen N; Southern PJ
Virology; 1997 May; 231(2):290-300. PubMed ID: 9168891
[TBL] [Abstract][Full Text] [Related]
59. Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from CTL recognition.
Velloso LM; Michaëlsson J; Ljunggren HG; Schneider G; Achour A
J Immunol; 2004 May; 172(9):5504-11. PubMed ID: 15100292
[TBL] [Abstract][Full Text] [Related]
60. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
